Printer Friendly
The Free Library
19,607,050 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

FDA advisory panel meeting scheduled for FS069.


SAN DIEGO--(BUSINESS WIRE)--Jan. 9, 1997--Molecular Biosystems Inc. (NYSE NYSE

See: New York Stock Exchange
:MB) (MBI) Thursday announced that the company received notification from the United States Food and Drug Administration United States Food and Drug Administration (FDA),
n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics.
 (FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
) that it has scheduled an advisory panel review for MBI's second generation ultrasound contrast agent, FS069, on Feb. 24, 1997.

The Radiology Device Advisory Panel will review the use of FS069 for use with 2-D echocardiography Echocardiography Definition

Echocardiography is a diagnostic test that uses ultrasound waves to create an image of the heart muscle. Ultrasound waves that rebound or echo off the heart can show the size, shape, and movement of the heart's valves and
 (ultrasound of the heart). This is the first in a series of cardiovascular and radiology indications for FS069 for which MBI will be seeking approval from the FDA. The indications will include myocardial myocardial /myo·car·di·al/ (-kahr´de-al) pertaining to the muscular tissue of the heart.

myocardial

pertaining to the muscular tissue of the heart (the myocardium).
 perfusion and enhancement of liver and kidney ultrasound imaging. Following FDA approval, Mallinckrodt Inc. (NYSE:MKG) will market and sell FS069 in the United States.

Molecular Biosystems, based in San Diego, is a leader in the development and manufacture of ultrasound contrast agents for medical imaging. ALBUNEX, the first FDA approved ultrasound imaging agent, is currently marketed in the United States by Mallinckrodt Inc.

CONTACT: Molecular Biosystems Inc., San Diego

Gerard A. Wills/Stephen F. Keane, 619/824-2212
COPYRIGHT 1997 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1997, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 9, 1997
Words:175
Previous Article:Barron America stands up for consumers and smashes through price barriers for powerful, feature-packed American-made PCs.
Next Article:Ostex International Announces Expansion of Activities in Europe and South America; Executives Hired to Manage Sales and Marketing in UK and Latin...
Topics:



Related Articles
Silicone breast implants on trial.
NIH advisers endorse disputed vaccine trial.
Betaseron near formal approval.
Panel OKs diet drug.
Immune-Based Therapies: FDA Meeting October 16.
MINIMED OPENS STRONG THEN FADES FOR MILD GAIN.
ROCKETDYNE HEALTH STUDY SET TO BE RELEASED FRIDAY.
FDA IGNORES DIABETICS' PLEAS, SAYS TESTING DEVICE NEEDS WORK.
FDA advisory hearing on new-fill (Sculptra), March 25, 2004 in Gaithersburg, Maryland.
Tipranavir: FDA Advisory Committee will meet may 19, hear experts, public comment.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles